FEBUXOSTAT TEVA-RATIOPHARM
As listed in the register: FEBUXOSTAT TEVA-RATIOPHARM 120 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
120 mg · comprimido recubierto con película
- Prescription only
- Muscles, joints and bones
- Active substance
- Febuxostat
- Used in
- Muscles, joints and bones
- Made by
- Teva B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (febuxostat). It describes the substance, not this exact product.
Febuxostat, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid.
Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
Febuxostat is extensively metabolized by both conjugation via uridine diphosphate glucuronosyltransferase (UGT) enzymes including UGT1A1, UGT1A3, UGT1A9, and UGT2B7 and oxidation via cytochrome P450 (CYP) enzymes including CYP1A2, 2C8 and 2C9 and non-P450 enzymes.
Febuxostat is eliminated by both hepatic and renal pathways.
Following multiple 80 mg once daily doses with a high fat meal, there was a 49% decrease in C max and an 18% decrease in AUC, respectively.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-04-27
Safety of the active substance
From the US prescribing label for the same active substance (febuxostat). It describes the substance, not this exact product.
WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions ( 5.1 )].
- Febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine.
- ( 4 ) Febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions ( 7 )].
Most Common Adverse Reactions In three randomized, controlled clinical studies (Studies 1, 2 and 3), which were 6 to 12 months in duration, the following adverse reactions were reported by the treating physician as related to study drug.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands7 matching products
- Adenuric 120 mg 120 mg · filmomhulde tablet
- Febuxostat Krka 120 mg 120 mg · filmomhulde tablet
- Febuxostat Laboratorios Liconsa 120 mg filmomhulde tabletten 120 mg · filmomhulde tablet
- Febuxostat Liconsa 120 mg filmomhulde tabletten 120 mg · filmomhulde tablet
- Febuxostat Teva 120 mg 120 mg · filmomhulde tablet
- Febuxostat Viatris 120 mg 120 mg · filmomhulde tablet
- Febuxostat Vivanta 120 mg filmomhulde tabletten 120 mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Teva B.V. |
|---|---|
| Active substance | Febuxostat |
| Used in | Muscles, joints and bones |
| Strength | 120 mg |
| Form | comprimido recubierto con película |
| Classification | M04AA03 · Muscles, joints and bones |
| Route | vía oral |
| Marketed | Yes, according to the register |
| Generic | Yes — a generic medicine, according to the register |
| Name in the register | FEBUXOSTAT TEVA-RATIOPHARM 120 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG |
| Nº Registro | 83255 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- comprimido recubierto con película2 products
- 80 mg
- 120 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.